The next generation biopharmaceuticals

Projects Affibody's pipeline

Affibody is strategically focused on advancing our pipeline of radioligand therapeutics that offer a competitive advantage and significant opportunities to benefit cancer patients. Our pipeline also includes partnership programs in immunology.

Pipeline

Affibody Upcoming events

event

27 Mar

AAD Annual Meeting 2026 March 27-31, 2026, Denver, USA

event

29 May

ASCO Annual Meeting 2026 May 29–June 2, 2026, Chicago, USA

event

30 May

SNMMI Annual Meeting 2026 May 30–June 2, 2026, Los Angeles, USA

There are currently no posts in the reports and events archive.

About Affibody Further Information

Our R&D focus on radioligand therapeutics

Latest news from Affibody

Regulatory

2026-02-19

Affibody Signs Letter of Intent with SHINE Technologies for Supply of Lutetium-177

Stockholm, Sweden, February 19, 2026. Affibody AB (“Affibody”) today announced that a Letter of Intent (LOI) has been signed with SHINE Technologies, LCC (“SHINE”)...[read more]

Previous press & news

Regulatory

2026-02-17

Affibody’s licensee Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

Stockholm, Sweden, February 17, 2026. Affibody’s licensee Rallybio Corporation (Rallybio) has today announced positive results...[read more]

News

2026-02-12

Affibody Medical announces outcome of rights issue

Stockholm, Sweden, February 12, 2026. Affibody Medical AB (publ) (”Affibody” or the “Company”) today announced...[read more]

All press & news

Career Work at Affibody

It is the competence and the engagement of all coworkers that make Affibody an inspiring and exciting place to work at. We know we reach much further in innovation, efficiency, and quality by having a work place where we as coworkers care for each other, are ambitious and know and value our own contribution to the end result.

Career